ReviewCurrent medicinal chemistry2026
Next-generation Approaches in Targeting Polycystic Ovarian Syndrome: Innovative Strategies.
Review in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating evidence-based lifestyle and adjunct therapies for long-term management of polycystic ovary syndrome: mechanistic insights and clinical implications.Frontiers in reproductive health · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder that affects millions of women worldwide and is characterized by ovarian dysfunction, hyperandrogenism, and metabolic abnormalities. The traditional diagnostic and therapeutic approaches often fail to address the multifaceted nature of PCOS. Recent advancements in next-generation sequencing (NGS), bioinformatics, and precision medicine have paved the way for innovative research and therapeutic strategies that promise to revolutionize PCOS management. This review focuses on exploring the genetic and molecular mechanisms of PCOS using innovative methodologies, such as genome-wide association studies (GWAS), transcriptomics, and computational approaches. Integrating big data analytics and machine learning algorithms enhances the predictive accuracy of PCOS diagnoses and treatment outcomes. In addition, the emergence of personalized medicine has enabled tailored therapeutic interventions based on individual genetic profiles and phenotypic expression. Furthermore, we explored the development of novel pharmacological agents and combinational therapies to enhance the understanding of PCOS pathophysiology. These approaches also focus on reducing inflammation, improving insulin sensitivity, and optimizing hormonal balance to achieve optimal health outcomes. The potential of digital health tools, including mobile applications and wearable technologies, to support self-monitoring and patient engagement in PCOS management is also highlighted. In conclusion, the integration of next-generation technologies and innovative research is necessary to transform the field of PCOS diagnosis and treatment, offering hope for more effective and individualized care. These underscore the importance of continued investment in advanced research methodologies and the adoption of personalized therapeutic strategies to address the complexities of PCOS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.